PRECIGEN, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
PRECIGEN, INC. (PGEN) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $1.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-04
- PRECIGEN, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $1.35M, a 3.61% increase year-over-year.
- PRECIGEN, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $1.30M.
- PRECIGEN, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-03-31 was $474.00K.
- PRECIGEN, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $1.78M.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|
| 2026-06-30 | $1.35M 10-Q · filed 2026-08-04 | $1.50M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $1.78M 10-K · filed 2026-03-25 | ||
| 2025-06-30 | $1.30M 10-Q · filed 2026-08-04 | $1.78M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $474.00K 10-Q · filed 2026-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |